Extremes of age decrease survival in adults after lung transplant. DSA were detected in 22/67 (32.8%) LTR within 1\year posttransplant. Of these, 9/41 (21.9%) MK-3207 occurred in the induction therapy group and 13/26 (50%) in the noninduction group. Class II DSA were detected in 3/41 (7.3%) LTR who received induction compared to 9/26 (34.6%) LTR without induction immunosuppression (level set at 0.05 for statistical significance. 3.?RESULTS 3.1. Patient demographics and clinical characteristics Sixty seven consecutive LTR between January 2016 and December MK-3207 2017 were included in the study Baseline demographic and clinical characteristics of the study participants are summarized in Table?1. A total of 41/67 (61%) LTR received Induction immunosuppression using a single dose rATG (1.5?mg/kg) within 24?h of transplant. The median age of LTR that received Induction immunosuppression was significantly higher compared to LTR with no induction (65 vs. 57 respectively; valueof the number of HLA class I and II matches between lung transplant recipients and donors. gMean values and in between brackets. hDiagnosis by UNOS listing category. Number and MK-3207 percent of lung transplant recipients with (A) obstructive lung disease (B) pulmonary vascular disease (C) infectious disease (D) restrictive lung disease. iSpecific lung disease diagnosis. Number and percent of lung transplant recipients with 1Bronchiectasis, 2Cystic fibrosis, 3Pulmonary fibrosisother causes, 4Chronic lung allograft dysfunctionlung retransplant, 5Chronic obstructive pulmonary disease, 6Constrictive bronchiolitis, 7Sarcoidosis, 8Obliterative bronchiolitis, 9Connective tissue disease\associated interstitial lung disease, and 10Idiopathic pulmonary fibrosis. jNumber of recipients received single or double lung transplant and percent in between brackets. 3.2. Effect of induction immunosuppression on de novo HLA DSA postlung transplantation De novo HLA DSA were detected in 22/67 (32.8%) LTR within 1\year posttransplant (Table?2). They were detected in 9/41 (21.9%) compared to 13/26 (50%) LTR with and without induction immunosuppression, respectively (Figure?2; valueof the number of days post\transplant for detection of de novo DSA. 3.3. Induction immunosuppression, survival, and CLAD Among LTR who received induction, 10/41 (24.4%) died within 3 years posttransplant compared to 9/26 (34.6%) without induction immunosuppression. The causes of death are summarized in Table?3. The overall three\year percent survival rates were 80.7% (95% confidence interval [CI]: 68.6%C95%) and 61.5% (95% CI: 42.3%C89.5%) for LTR with and without induction immunosuppression, respectively (Figure?3A). The presence of CLAD was assessed in 56/67 LTR. CLAD was diagnosed in 22/56 (39.3%) LTR within 3 years posttransplant. CLAD was ungradable in 11/67 patients due to airway stenosis or the presence of a tracheostomy tube. Among patients with CLAD, 18/22 (81.8%) had BOS, 3/22 (13.6%) had RAS, 1/22 (4.5%) had a mixed obstructive and restrictive phenotype. The 3\year freedom from CLAD rates were 49% (95% CI: 34%C71%) and 56% (95% CI: 35%C90%) for LTR with and without induction immunosuppression, respectively (Figure?3B). The differences in overall survival and freedom from CLAD rates between LTR and without induction immunosuppression were not statistically significant before or after adjusting for age or LAS differences. Open in a separate window Figure 3 The KaplanCMeier curve of (A) overall percent survival and (B) percent freedom from CLAD up to 3 years posttransplant. The 3\year percent survival rates were 80.7% (68.6C95) and 61.5% (42.3C89.5) for LTR with and without induction immunosuppression, respectively. Rabbit Polyclonal to BCLAF1 The 3\year percent freedom from CLAD rates were 49% (34C71) and 56% (35C90) for LTR with and without induction immunosuppression, respectively. Differences were not statistically significant (p?>?.05). CLAD, chronic lung allograft dysfunction; LTR, lung transplant recipient Table 3 Summary of cause of death
Acute cellular rejection02Acute peritonitis10ARDS11Bacterial Pneumonia01CLAD13CMV pneumonitis10End\stage liver disease11Humoral rejection11Ischemic colitis10Massive hemoptysis10Myelodysplastic syndrome10Non\small cell lung cancer01 Open in a separate window Abbreviations: ARDS, acute respiratory distress syndrome CLAD, chronic lung allograft dysfunction; MK-3207 CMV, cytomegalovirus. 4.?DISCUSSION This is the first report exploring the association of induction immunosuppression with de novo DSA production and long term clinical outcomes. We report a significant reduction in de novo DSA production in LTR who received a modified regimen of a single\dose rATG induction immunosuppression. A better understanding of antibody\mediated allograft damage in LTR in the last few years has translated into multiple investigations highlighting the deleterious effects of de novo DSA in this population. Clinically, in the same time frame, we have witnessed.